<DOC>
	<DOCNO>NCT02445352</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety DP-R207 patient primary hypercholesterolemia .</brief_summary>
	<brief_title>Efficacy/Safety DP-R207 Tablet Versus CRESTOR Tablet Patients With Primary Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Aged 19 year Signed informed consent form At visit 1 visit 2 , LDLCholesterol ≤ 250mg/dL Triglyderide ≤ 350mg/dL Has history hypersensitivity HMGCoA reductase inhibitor component ezeimibe Liver transaminases &gt; 2 x upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>